HomeGLPG • NASDAQ
add
Galapagos NV - ADR
Previous close
$24.50
Day range
$24.51 - $24.91
Year range
$22.36 - $31.23
Market cap
1.62B USD
Avg Volume
282.88K
Market news
Financials
Income Statement
Revenue
Net income
| (EUR) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 75.50M | — |
Operating expense | 359.50M | — |
Net income | 25.31M | — |
Net profit margin | 33.52 | — |
Earnings per share | 0.29 | 132.61% |
EBITDA | -53.03M | — |
Effective tax rate | -0.49% | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 3.12B | -15.39% |
Total assets | 4.14B | -5.09% |
Total liabilities | 1.24B | -20.68% |
Total equity | 2.90B | — |
Shares outstanding | 65.90M | — |
Price to book | 0.56 | — |
Return on assets | -3.70% | — |
Return on capital | -5.32% | — |
Cash Flow
Net change in cash
| (EUR) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | 25.31M | — |
Cash from operations | -59.37M | — |
Cash from investing | 68.36M | — |
Cash from financing | -1.60M | — |
Net change in cash | 8.72M | — |
Free cash flow | 1.12M | — |
About
Galapagos NV is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.
The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis. Wikipedia
Founded
1999
Website
Employees
704
